Northland Capital Downgrades Astera Labs Inc (ALAB) to a Market perform from an Outperform

Astera Labs Inc’s recent filing unveils that its Director ALBA MANUEL unloaded Company’s shares for reported $31.71 million on Sep 02 ’25. In the deal valued at $173.27 per share,183,000 shares were sold. As a result of this transaction, ALBA MANUEL now holds 385,863 shares worth roughly $89.25 million.

Then, Mazzara Philip sold 10,000 shares, generating $1,886,956 in total proceeds. Upon selling the shares at $188.70, the General Counsel and Secretary now owns 161,573 shares.

Before that, CASA ALAMEDA 2007, LLC bought 33,000 shares. Astera Labs Inc shares valued at $6,012,600 were divested by the Director at a price of $182.20 per share.

Northland Capital downgraded its Astera Labs Inc [ALAB] rating to a Market perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late May with a ‘”an Outperform”‘ rating. Susquehanna began covering ALAB with “Neutral” recommendation on May 16, 2025. Morgan Stanley revised its rating on May 12, 2025. It rated ALAB as “an Overweight” which previously was an “an Equal-weight”.

Price Performance Review of ALAB

On Monday, Astera Labs Inc [NASDAQ:ALAB] saw its stock jump 0.78% to $231.29. Over the last five days, the stock has gained 7.03%. Astera Labs Inc shares have risen nearly 451.08% since the year began. Nevertheless, the stocks have risen 74.62% over the past one year.

How much short interest is there in Astera Labs Inc?

A steep rise in short interest was recorded in Astera Labs Inc stocks on 2025-08-29, dropping by 73818.0 shares to a total of 9.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 9.28 million shares. There was a decline of -0.8%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on March 14, 2025 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $82 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.